Market Size of Global Peptide Synthesis Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Peptide Synthesis Market Analysis
The peptide synthesis market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).
Peptides were increasingly being developed and repurposed in search of therapeutics for the treatment of COVID-19. For instance, as per the August 2022 update from Clinical Trials.gov, more than 100 peptide drugs are in development for the treatment of COVID-19, including 15 synthetic peptides for acute respiratory distress syndrome (ARDS), a life-threatening condition where the lungs cannot provide the body's vital organs with enough oxygen, and other respiratory illnesses caused by SARS-Cov-2 infection. Additionally, the article published in 2022 under the title "Peptide-Based Vaccines and Therapeutics for COVID-19" stated that because of the urgent need for alternative COVID-19 therapy peptides are found to be useful due to their target selectivity, improved interactions, and reduced toxicity. Peptides' quick metabolism can be slowed down and given long-acting properties with minor structural changes. Hence as per the information quoted above, COVID-19 had a significant impact on the peptide synthesis market.
The major growth of the market is a steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries. The peptides have a wide range of applications in the treatment of various lifestyle disorders, such as cancers, diabetes, and obesity. The increasing incidence of these metabolic and lifestyle disorders is paving the way for the application of peptide therapeutics in oncology and metabolic disorders. For instance, according to the International Diabetes Federation statistics published in 2021, 537 million adults (20-79 years) were living with diabetes globally. This constituted 1 in 10 people affected with diabetes. As per the same source, 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. Several peptide therapies, such as Glucagon-like peptide-1amide, release postprandially that stimulates insulin secretion, and they are popular in pancreatic therapy. As a result, the demand for peptide drugs are anticipated to rise as the number of diabetic patients grows, which is likely to drive the market throughout the forecast period.
The increased research activities and novel product approvals due to the rise in funding for research and development and the advantages of advanced peptide synthesizers have further boosted the growth of the peptide synthesis market throughout the period. For instance, in April 2021, ISSAR Pharma announced that they were licensing their peptide-based New Chemical Entities (NCEs), with pre-investigational new drug (IND) filing and the United States patent. Thus, such significant developments in peptide drugs are expected to boost the market demand.
However, the issues about large-scale peptide synthesis and the lack of a robust distribution network restrain the market growth over the forecast period.
